Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2023 Jan;27(1):8.
doi: 10.3892/mmr.2022.12895. Epub 2022 Nov 11.

Comparing tumor microRNA profiles of patients with long‑ and short‑term‑surviving glioblastoma

Björn Schneider  1 , Nora Lamp  1 , Annette Zimpfer  1 , Christian Henker  2 , Andreas Erbersdobler  1
Affiliations
Comparative Study

Comparing tumor microRNA profiles of patients with long‑ and short‑term‑surviving glioblastoma

Björn Schneider et al. Mol Med Rep. 2023 Jan.

Abstract

Glioblastoma is one of the most frequent primary brain tumors with a poor prognosis. Nevertheless, some patients show a prolonged survival. The aim of the present study was to compare the expression profiles of tumor derived microRNA (miR) of long‑term survivors with those of short‑term survivors in order to identify differentially expressed miRs as well as their target genes, which may elucidate mechanisms that play a role in varying tumor progression and, therefore, may influence survival. Formalin‑fixed paraffin‑embedded samples of 23 patients with glioblastoma were classified according to overall survival. Profiles of miR expression were determined using Nanostring technology. Expression levels of potential target genes of differentially expressed miRs were assessed using immunohistochemistry. MiR profiles of long‑term survivors differed from those of short‑term survivors. A total of three prominent differentially expressed miRs were highlighted: MiR‑130b‑3p, which is downregulated in long‑term survivors, and miR‑146b‑5p and miR‑148a‑3p, which are upregulated in long‑term survivors. Known tumor suppressor genes are among targets potentially affected by miR‑130b‑3p, whereas targets of miR‑146b‑5p and miR‑148a‑3p consist of several genes known to have a role in tumor invasion and aggressiveness. In conclusion, it was revealed that a type of miR‑signature was associated with short‑ and long‑term survival, potentially serving as biomarker for disease progression and providing a base for further functional studies.

Keywords: expression profile; glioblastoma; microRNAs; molecular signature; overall survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
Boxplot representation of normalized expression values of miR-130b-3p, miR-146b-5p and miR-148a-3p, comparing LTS and STS groups. Center lines indicate medians, box limits indicate the 25 and 75th percentiles, whiskers extend 1.5× interquartile range from percentiles and dots represent outliers (generated using BoxPlotR; http://shiny.chemgrid.org/boxplotr/). *P<0.05. miR, microRNA; STS, short-term survivor; LTS, long-term survivor.
Figure 2.
Figure 2.
Visualization of the signature model miR-130b-3p low, miR-146b-5p high, miR-148a-3p high or vice versa. Each column represents a patient, and the number indicates for how many of the three miRs the model statement is true. Blue=long-term survivor; yellow=short-term survivor; green=low expression; red=high expression. miR, microRNA.
Figure 3.
Figure 3.
PTEN immunohistochemistry, sorted, from left to right, in an ascending order of miR-130b-3p counts days in patients #1 to 23. miR, microRNA; OS, overall survival; STS, short-term survivor; LTS, long-term survivor; d, days.
Figure 4.
Figure 4.
TRAF6 immunohistochemistry, sorted, from left to right, in an ascending order of miR-146b-5p counts in patients #1 to 23. miR, microRNA; OS, overall survival; STS, short-term survivor; LTS, long-term survivor; d, days; TRAF6, TNF receptor-associated factor 6.
See this image and copyright information in PMC

References

    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7. - DOI - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, et al. Glioblastoma in adults: A society for neuro-oncology (SNO) and european society of neuro-oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073–1113. doi: 10.1093/neuonc/noaa106. - DOI - PMC - PubMed
    1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21((Suppl 5)):v1–v100. doi: 10.1093/neuonc/noz150. - DOI - PMC - PubMed
    1. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, Barnholtz-Sloan JS. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406. doi: 10.3322/caac.21693. - DOI - PubMed

Publication types

LinkOut - more resources